Allosteric modulators of the class A G protein coupled receptors

Advances in Experimental Medicine and Biology

Volumn 917, Issue , 2016, Pages 185-207

  Tschammer, Nuska ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Allosteric modulation; Allosteric modulators; G protein coupled receptors; Protein protein interaction; Therapeutics

Indexed keywords

ADENOSINE A2A RECEPTOR; ANTIBODY; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; CALCIUM; CHEMOKINE RECEPTOR CXCR4; CHOLESTEROL; CINACALCET; G PROTEIN COUPLED RECEPTOR; KAPPA OPIATE RECEPTOR; LIPID; MARAVIROC; PEPTIDE; PLERIXAFOR; REPARIXIN; SODIUM; STEROID; ZINC;

ALLOSTERISM; CHANNEL GATING; COMPLEX FORMATION; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; DIMERIZATION; DRUG BINDING SITE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERPARATHYROIDISM; INTRACELLULAR SIGNALING; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RADIOASSAY; RADIOLIGAND BINDING ASSAY; RECEPTOR BINDING ASSAY; ALLOSTERIC SITE; ANIMAL; CHEMISTRY; DRUG DESIGN; DRUG EFFECTS; METABOLISM; PHYSIOLOGY;

ALLOSTERIC REGULATION; ALLOSTERIC SITE; ANIMALS; DRUG DESIGN; HUMANS; RECEPTORS, G-PROTEIN-COUPLED;

EID: 85019221329     PISSN: 00652598     EISSN: 22148019     Source Type: Book Series    
DOI: 10.1007/978-3-319-32805-8_9     Document Type: Chapter

References (107)

1. Fredriksson R, Lagerström MC, Lundin L-G, Schiöth HB (2003) The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. Mol Pharmacol 63:1256-1272
2. Lagerström MC, Schiöth HB (2008) Structural diversity of G protein-coupled receptors and significance for drug discovery. Nat Rev Drug Discov 7:339-357
3. Christopoulos A, Kenakin T (2002) G protein-coupled receptor allosterism and complexing. Pharmacol Rev 54:323-374
4. Overington JP, Al-Lazikani B, Hopkins AL (2006) How many drug targets are there? Nat Rev Drug Discov 5:993-996
5. Hurowitz EH, Melnyk JM, Chen YJ, Kouros-Mehr H, Simon MI, Shizuya H (2000) Genomic characterization of the human heterotrimeric G protein alpha, beta, and gamma subunit genes. DNA Res 7:111-120
6. Robishaw JD, Berlot CH (2004) Translating G protein subunit diversity into functional specificity. Curr Opin Cell Biol 16:206-209
7. Simon MI, Strathmann MP, Gautam N (1991) Diversity of G proteins in signal transduction. Science 252:802-808
8. Brandt DR, Ross EM (1985) GTPase activity of the stimulatory GTP-binding regulatory protein of adenylate cyclase, Gs. Accumulation and turnover of enzyme-nucleotide intermediates. J Biol Chem 260:266-272
9. Dupré DJ, Robitaille M, Rebois RV, Hébert TE (2009) The role of Gbetagamma subunits in the organization, assembly, and function of GPCR signaling complexes. Annu Rev Pharmacol Toxicol 49:31-56
10. Marinissen MJ, Gutkind JS (2001) G-protein-coupled receptors and signaling networks: emerging paradigms. Trends Pharmacol Sci 22:368-376
11. Shenoy SK, Lefkowitz RJ (2011) β-Arrestin-mediated receptor trafficking and signal transduction. Trends Pharmacol Sci 32:521-533
12. Rajagopal S, Rajagopal K, Lefkowitz RJ (2010) Teaching old receptors new tricks: biasing seven-transmembrane receptors. Nat Rev Drug Discov 9:373-386
13. Kenakin T, Christopoulos A (2013) Signalling bias in new drug discovery: detection, quantification and therapeutic impact. Nat Rev Drug Discov 12:205-216
14. Kenakin T (2011) Functional selectivity and biased receptor signaling. J Pharmacol Exp Ther 336:296-302
15. Kenakin T, Miller LJ (2010) Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery. Pharmacol Rev 62:265-304
16. Wang CIA, Lewis RJ (2013) Emerging opportunities for allosteric modulation of G-protein coupled receptors. Biochem Pharmacol 85:153-162
17. Kenakin T (2005) New concepts in drug discovery: collateral efficacy and permissive antagonism. Nat Rev Drug Discov 4:919-927
18. Kenakin TP (2009) ′7TM receptor allostery: putting numbers to shapeshifting proteins. Trends Pharmacol Sci 30:460-469
19. Bridges TM, Lindsley CW (2008) G-protein-coupled receptors: from classical modes of modulation to allosteric mechanisms. ACS Chem Biol 3:530-541
20. Leach K, Sexton PM, Christopoulos A (2007) Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology. Trends Pharmacol Sci 28:382-389
21. Wootten D, Christopoulos A, Sexton PM (2013) Emerging paradigms in GPCR allostery: implications for drug discovery. Nat Rev Drug Discov 12:630-644
22. Spalding TA, Trotter C, Skjaerbaek N, Messier TL, Currier EA, Burstein ES, Li D, Hacksell U, Brann MR (2002) Discovery of an ectopic activation site on the M(1) muscarinic receptor. Mol Pharmacol 61:1297-1302
23. Moriconi A, Cesta MC, Cervellera MN, Aramini A, Coniglio S, Colagioia S, Beccari AR, Bizzarri C, Cavicchia MR, Locati M, Galliera E, Di Benedetto P, Vigilante P, Bertini R, Allegretti M (2007) Design of noncompetitive interleukin-8 inhibitors acting on CXCR1 and CXCR 2. J Med Chem 50:3984-4002
24. Litschig S, Gasparini F, Rueegg D, Stoehr N, Flor PJ, Vranesic I, Prézeau L, Pin JP, Thomsen C, Kuhn R (1999) CPCCOEt, a noncompetitive metabotropic glutamate receptor 1 antagonist, inhibits receptor signaling without affecting glutamate binding. Mol Pharmacol 55:453-461
25. May LT, Leach K, Sexton PM, Christopoulos A (2007) Allosteric modulation of G protein-coupled receptors. Annu Rev Pharmacol Toxicol 47:1-51
26. Watson C, Jenkinson S, Kazmierski W, Kenakin T (2005) The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor. Mol Pharmacol 67:1268-1282
27. Gnagey A, Ellis J (1996) Allosteric regulation of the binding of [3H]acetylcholine to m2 muscarinic receptors. Biochem Pharmacol 52:1767-1775
28. Gregory KJ, Sexton PM, Christopoulos A (2007) Allosteric modulation of muscarinic acetylcholine receptors. Curr Neuropharmacol 5:157-167
29. Jakubík J, Bacáková L, El-Fakahany EE, Tucek S (1997) Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors. Mol Pharmacol 52:172-179
30. Avlani V, May LT, Sexton PM, Christopoulos A (2004) Application of a kinetic model to the apparently complex behavior of negative and positive allosteric modulators of muscarinic acetylcholine receptors. J Pharmacol Exp Ther 308:1062-1072
31. Christopoulos A, Lanzafame A, Ziegler A, Mitchelson F (1997) Kinetic studies of co-operativity at atrial muscarinic M2 receptors with an “infinite dilution” procedure. Biochem Pharmacol 53:795-800
32. Lanzafame A, Christopoulos A, Mitchelson F (1997) Three allosteric modulators act at a common site, distinct from that of competitive antagonists, at muscarinic acetylcholine M2 receptors. J Pharmacol Exp Ther 282:278-285
33. Liu W, Chun E, Thompson AA, Chubukov P, Xu F, Katritch V, Han GW, Roth CB, Heitman LH, IJzerman AP, Cherezov V, Stevens RC (2012) Structural basis for allosteric regulation of GPCRs by sodium ions. Science 337:232-236
34. Conigrave AD, Quinn SJ, Brown EM (2000) L-amino acid sensing by the extracellular Ca2+-sensing receptor. Proc Natl Acad Sci U S A 97:4814-4819
35. Schetz JA, Sibley DR (1997) Zinc allosterically modulates antagonist binding to cloned D1 and D2 dopamine receptors. J Neurochem 68:1990-1997
36. Lanzafame AA, Guida E, Christopoulos A (2004) Effects of anandamide on the binding and signaling properties of M 1 muscarinic acetylcholine receptors. Biochem Pharmacol 68:2207-2219
37. Lane JR, Beukers MW, Mulder-Krieger T, IJzerman AP (2010) The endocannabinoid 2-arachidonylglycerol is a negative allosteric modulator of the human A3 adenosine receptor. Biochem Pharmacol 79:48-56
38. Rossi M, Dimida A, Ferrarini E, Silvano E, De Marco G, Agretti P, Aloisi G, Simoncini T, Di Bari L, Tonacchera M, Giorgi F, Maggio R (2009) Presence of a putative steroidal allosteric site on glycoprotein hormone receptors. Eur J Pharmacol 623:155-159
39. Cloëz-Tayarani I, Cardona A, Rousselle JC, Massot O, Edelman L, Fillion G (1997) Autoradiographic characterization of [3H]-5-HT-moduline binding sites in rodent brain and their relationship to 5-HT1B receptors. Proc Natl Acad Sci U S A 94:9899-9904
40. Massot O, Rousselle JC, Fillion MP, Grimaldi B, Cloëz-Tayarani I, Fugelli A, Prudhomme N, Seguin L, Rousseau B, Plantefol M, Hen R, Fillion G (1996) 5-hydroxytryptamine-moduline, a new endogenous cerebral peptide, controls the serotonergic activity via its specific interaction with 5-hydroxytryptamine1B/1D receptors. Mol Pharmacol 50:752-762
41. Goin JC, Borda E, Leiros CP, Storino R, Sterin-Borda L (1994) Identification of antibodies with muscarinic cholinergic activity in human Chagas’ disease: pathological implications. J Auton Nerv Syst 47:45-52
42. Leiros CP, Sterin-Borda L, Borda ES, Goin JC, Hosey MM (1997) Desensitization and sequestration of human m2 muscarinic acetylcholine receptors by autoantibodies from patients with Chagas’ disease. J Biol Chem 272:12989-12993
43. Pert CB, Pasternak G, Snyder SH (1973) Opiate agonists and antagonists discriminated by receptor binding in brain. Science 182:1359-1361
44. Katritch V, Fenalti G, Abola EE, Roth BL, Cherezov V, Stevens RC (2014) Allosteric sodium: a key co-factor in class A GPCR signaling. Trends Biochem Sci 39(5):233-244
45. Gutiérrez-de-Terán H, Massink A, Rodríguez D, Liu W, Han GW, Joseph JS, Katritch I, Heitman LH, Xia L, Ijzerman AP, Cherezov V, Katritch V, Stevens RC (2013) The role of a sodium ion binding site in the allosteric modulation of the A2A adenosine G protein-coupled receptor. Structure 21:2175-2185
46. Gao ZG, Melman N, Erdmann A, Kim SG, Müller CE, IJzerman AP, Jacobson KA (2003) Differential allosteric modulation by amiloride analogues of agonist and antagonist binding at A1 and A3 adenosine receptors. Biochem Pharmacol 65:525-534
47. Tsai BIES, Lefkowitz RJ (1978) Agonist-specific effects of monovalent and divalent cations on adenylate cyclase-coupled alpha adrenergic receptors in rabbit platelets. Mol Pharmacol 14:540-548
48. Horstman DA, Brandon S, Wilson AL, Guyer CA, Cragoe EJ, Limbird LE (1990) An aspartate conserved among G-protein receptors confers allosteric regulation of alpha 2-adrenergic receptors by sodium. J Biol Chem 265:21590-21595
49. Ceresa BP, Limbird LE (1994) Mutation of an aspartate residue highly conserved among G-protein-coupled receptors results in nonreciprocal disruption of alpha 2-adrenergic receptor-G-protein interactions. A negative charge at amino acid residue 79 forecasts alpha 2A-adrenergic recep. J Biol Chem 269:29557-29564
50. Neve KA (1991) Regulation of dopamine D2 receptors by sodium and pH. Mol Pharmacol 39:570-578
51. Neve KA, Cumbay MG, Thompson KR, Yang R, Buck DC, Watts VJ, DuRand CJ, Teeter MM (2001) Modeling and mutational analysis of a putative sodium-binding pocket on the dopamine D2 receptor. Mol Pharmacol 60:373-381
52. Martin S, Botto JM, Vincent JP, Mazella J (1999) Pivotal role of an aspartate residue in sodium sensitivity and coupling to G proteins of neurotensin receptors. Mol Pharmacol 55:210-215
53. Quitterer U, AbdAlla S, Jarnagin K, Müller-Esterl W (1996) Na+ ions binding to the bradykinin B2 receptor suppress agonist-independent receptor activation. Biochemistry 35:13368-13377
54. Ballesteros JA, Weinstein H (1995) Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors. Methods Neurosci 25:366-428
55. Held C, Hervet M, Plomer M, Tschammer N, Harald H, Gmeiner P, Einsiedel J, Hübner H (2011) Discovery of highly potent and neurotensin receptor 2 selective neurotensin mimetics. J Med Chem 54:2915-2923
56. Zhang C, Srinivasan Y, Arlow DH, Fung JJ, Palmer D, Zheng Y, Green HF, Pandey A, Dror RO, Shaw DE, Weis WI, Coughlin SR, Kobilka BK (2012) High-resolution crystal structure of human protease-activated receptor 1. Nature 492:387-392
57. Miller-Gallacher JL, Nehmé R, Warne T, Edwards PC, Schertler GFX, Leslie AGW, Tate CG (2014) The 2.1 Å resolution structure of cyanopindolol-bound β1-adrenoceptor identifies an intramembrane Na+ ion that stabilises the ligand-free receptor. PLoS One 9:e92727
58. Fenalti G, Giguere PM, Katritch V, Huang X-P, Thompson A, Cherezov V, Roth BL, Stevens RC (2014) Molecular control of Δ-opioid receptor signalling. Nature 506:191-196
59. Xu F, Wu H, Katritch V, Han GW, Jacobson KA, Gao Z-G, Cherezov V, Stevens RC (2011) Structure of an agonist-bound human A2A adenosine receptor. Science 332:322-327
60. Rasmussen SGF, DeVree BT, Zou Y, Kruse AC, Chung KY, Kobilka TS, Thian FS, Chae PS, Pardon E, Calinski D, Mathiesen JM, Shah STA, Lyons JA, Caffrey M, Gellman SH, Steyaert J, Skiniotis G, Weis WI, Sunahara RK, Kobilka BK (2011) Crystal structure of the β2 adrenergic receptor-Gs protein complex. Nature 477:549-555
61. Montaner S, Kufareva I, Abagyan R, Gutkind JS (2013) Molecular mechanisms deployed by virally encoded G protein-coupled receptors in human diseases. Annu Rev Pharmacol Toxicol 53:331-354
62. Lo S, Hu H, Tschammer N, Gmeiner P, Löber S, Hübner H (2011) Recent advances in the search for D3-and D4-selective drugs: probes, models and candidates. Trends Pharmacol Sci 32:148-157
63. Quantifying functional selectivity (biased agonism) Terry Kenakin 1, Steve Novick 2, Arthur Christopoulos 3 1
64. Gardner RC, Assinder SJ, Christie G, Mason GG, Markwell R, Wadsworth H, McLaughlin M, King R, Chabot-Fletcher MC, Breton JJ, Allsop D, Rivett AJ (2000) Characterization of peptidyl boronic acid inhibitors of mammalian 20 S and 26 S proteasomes and their inhibition of proteasomes in cultured cells. Biochem J 346(Pt 2):447-454
65. Takeda A (2000) Movement of zinc and its functional significance in the brain. Brain Res Rev 34:137-148
66. Palm R, Hallmans G (1982) Zinc concentrations in the cerebrospinal fluid of normal adults and patients with neurological diseases. J Neurol Neurosurg Psychiatry 45:685-690
67. Markesbery WR, Ehmann WD, Alauddin M, Hossain TIM (1984) Brain trace element concentrations in aging. Neurobiol Aging 5:19-28
68. Schetz JA, Chu A, Sibley DR (1999) Zinc modulates antagonist interactions with D2-like dopamine receptors through distinct molecular mechanisms. J Pharmacol Exp Ther 289:956-964
69. Liu Y, Teeter MM, DuRand CJ, Neve KA (2006) Identification of a Zn2+-binding site on the dopamine D 2 receptor. Biochem Biophys Res Commun 339:873-879
70. Holst B, Elling CE, Schwartz TW (2002) Metal ion-mediated agonism and agonist enhancement in melanocortin MC1 and MC4 receptors. J Biol Chem 277:47662-47670
71. Fowler CB, Pogozheva ID, LeVine H, Mosberg HI (2004) Refinement of a homology model of the Μ-opioid receptor using distance constraints from intrinsic and engineered zinc-binding sites. Biochemistry 43:8700-8710
72. Peacock M (2010) Calcium metabolism in health and disease. Clin J Am Soc Nephrol 5(Suppl 1):S23-S30
73. Galvez T, Urwyler S, Prézeau L, Mosbacher J, Joly C, Malitschek B, Heid J, Brabet I, Froestl W, Bettler B, Kaupmann K, Pin JP (2000) Ca(2+) requirement for high-affinity gamma-aminobutyric acid (GABA) binding at GABA(B) receptors: involvement of serine 269 of the GABA(B)R1 subunit. Mol Pharmacol 57:419-426
74. Mun H-C, Franks AH, Culverston EL, Krapcho K, Nemeth EF, Conigrave AD (2004) The venus Fly trap domain of the extracellular Ca2+-sensing receptor is required for L-amino acid sensing. J Biol Chem 279:51739-51744
75. Grazzini E, Guillon G, Mouillac B, Zingg HH (1998) Inhibition of oxytocin receptor function by direct binding of progesterone. Nature 392:509-512
76. Gimpl G, Wiegand V, Burger K, Fahrenholz F (2002) Cholesterol and steroid hormones: modulators of oxytocin receptor function. Progress Brain Res 139:43-55
77. Pang L, Graziano M, Wang S (1999) Membrane cholesterol modulates galanin-GalR2 interaction. Biochemistry 38:12003-12011
78. Pucadyil TJ, Chattopadhyay A (2004) Cholesterol modulates ligand binding and G-protein coupling to serotonin1A receptors from bovine hippocampus. Biochim Biophys Acta Biomembr 1663:188-200
79. Hanson MA, Cherezov V, Griffith MT, Roth CB, Jaakola VP, Chien EYT, Velasquez J, Kuhn P, Stevens RC (2008) A specific cholesterol binding site is established by the 2.8 Å structure of the human β2-adrenergic receptor. Structure 16:897-905
80. Verma V, Mann A, Costain W, Pontoriero G, Castellano JM, Skoblenick K, Gupta SK, Pristupa Z, Niznik HB, Johnson RL, Nair VD, Mishra RK (2005) Modulation of agonist binding to human dopamine receptor subtypes by L-prolyl-L-leucyl-glycinamide and a peptidomimetic analog. J Pharmacol Exp Ther 315:1228-1236
81. Chiu S, Paulose CS, Mishra RK (1981) Effect of L-prolyl-L-leucyl-glycinamide (PLG) on neuroleptic-induced catalepsy and dopamine/neuroleptic receptor bindings. Peptides 2:105-111
82. Borda E, Pascual J, Cossio P, De La Vega M, Arana R, Sterin-Borda L (1984) A circulating IgG in Chagas’ disease which binds to beta-adrenoceptors of myocardium and modulates their activity. Clin Exp Immunol 57:679-686
83. Goin JC, Leiros CP, Borda E, Sterin-Borda L (1997) Interaction of human chagasic IgG with the second extracellular loop of the human heart muscarinic acetylcholine receptor: functional and pathological implications. FASEB J 11:77-83
84. Milligan G (2009) G protein-coupled receptor hetero-dimerization: contribution to pharmacology and function. Br J Pharmacol 158:5-14
85. Rivero-Müller A, Chou Y-Y, Ji I, Lajic S, Hanyaloglu AC, Jonas K, Rahman N, Ji TH, Huhtaniemi I (2010) Rescue of defective G protein-coupled receptor function in vivo by intermolecular cooperation. Proc Natl Acad Sci U S A 107:2319-2324
86. Palczewski K, Kumasaka T, Hori T, Behnke C (2000) Crystal structure of rhodopsin: AG protein-coupled receptor. Science 289:739-745
87. Wu B, Chien EYT, Mol CD, Fenalti G, Liu W, Katritch V, Abagyan RA, Brooun A, Wells P, Bi FC, Hamel DJ, Kuhn P, Handel TM, Cherezov V, Stevens RC (2010) Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science 330:1066-1071
88. Cherezov V, Rosenbaum DM, Hanson MA, Rasmussen SGF, Thian FS, Kobilka TS, Choi H-J, Kuhn P, Weis WI, Kobilka BK, Stevens RC (2007) High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science 318:1258-1265
89. Wu H, Wacker D, Mileni M, Katritch V, Han G (2012) Structure of the human Κ-opioid receptor in complex with JDTic. Nature 485:327-332
90. Schwartz TW, Holst B (2006) Ago-allosteric modulation and other types of allostery in dimeric 7TM receptors. J Recept Signal Transduct Res 26:107-128
91. Vilardaga J-P, Nikolaev VO, Lorenz K, Ferrandon S, Zhuang Z, Lohse MJ (2008) Conformational cross-talk between alpha2A-adrenergic and Mu-opioid receptors controls cell signaling. Nat Chem Biol 4:126-131
92. Koschatzky S, Tschammer N, Gmeiner P (2011) Cross-receptor interactions between dopamine D2L and neurotensin NTS1 receptors modulate binding affinities of dopaminergics. ACS Chem Neurosci 2(6):308-316
93. Armstrong D, Strange PG (2001) Dopamine D2 receptor dimer formation: evidence from ligand binding. J Biol Chem 276:22621-22629
94. Han Y, Moreira IS, Urizar E, Weinstein H, Javitch JA (2009) Allosteric communication between protomers of dopamine class a GPCR dimers modulates activation. Nat Chem Biol 5:688-695
95. Lane JR, Donthamsetti P, Shonberg J, Draper-Joyce CJ, Dentry S, Michino M, Shi L, López L, Scammells PJ, Capuano B, Sexton PM, Javitch JA, Christopoulos A (2014) A new mechanism of allostery in a G protein-coupled receptor dimer. Nat Chem Biol 10:745-752
96. AbdAlla S, Lother H, el Massiery A, Quitterer U (2001) Increased AT(1) receptor heterodimers in preeclampsia mediate enhanced angiotensin II responsiveness. Nat Med 7:1003-1009
97. AbdAlla S, Lother H, Quitterer U (2000) AT1-receptor heterodimers show enhanced G-protein activation and altered receptor sequestration. Nature 407:94-98
98. He L, Fong J, Von Zastrow M, Whistler JL (2002) Regulation of opioid receptor trafficking and morphine tolerance by receptor oligomerization. Cell 108:271-282
99. Waldhoer M, Fong J, Jones RM, Lunzer MM, Sharma SK, Kostenis E, Portoghese PS, Whistler JL (2005) A heterodimer-selective agonist shows in vivo relevance of G protein-coupled receptor dimers. Proc Natl Acad Sci U S A 102:9050-9055
100. Kenakin TP (2010) Ligand detection in the allosteric world. J Biomol Screen 15:119-130
101. Lazareno S, Birdsall NJ (1995) Detection, quantitation, and verification of allosteric interactions of agents with labeled and unlabeled ligands at G protein-coupled receptors: interactions of strychnine and acetylcholine at muscarinic receptors. Mol Pharmacol 48:362-378
102. Leach K, Sexton PM, Christopoulos A (2011) Quantification of allosteric interactions at G protein-coupled receptors using radioligand binding assays. Current protocols in pharmacology. 52:1.22:1.22.1-1.22.41. Wiley
103. Gregory KJ, Sexton PM, Christopoulos A (2010) Overview of receptor allosterism. Curr Protocols Pharmacol 51:1.21:1.21.1-1.21.34
104. Kenakin T, Watson C, Muniz-Medina V, Christopoulos A, Novick S (2012) A simple method for quantifying functional selectivity and agonist bias. ACS Chem Neurosci 3:193-203
105. Ehlert FJ (1988) Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods. Mol Pharmacol 33:187-194
106. Black JW, Leff P (1983) Operational models of pharmacological agonism. Proc R Soc Lond B Biol Sci 220:141-162
107. Ehlert FJ (2005) Analysis of allosterism in functional assays. J Pharmacol Exp Ther 315:740-754